The first edition of the “Aim for Innovations” competition initiated by Celon Pharma S.A. was just launched

Press release
Warsaw, May 2013

Celon Pharma S.A. announces a competition for research projects in the field of asthma and COPD.

Aim for Innovations is a nationwide competition which is a call for cooperation with industry directed at outstanding scientists in the fields of medical science, pharmaceutics, biology and biotechnology and which offers them a unique chance to implement research projects in search of breakthrough therapies along with Celon Pharma S.A. The first edition of the competition which is about to start is dedicated to inflammatory lung diseases.

Warsaw, May 2013 The competition is addressed to scientific centres and institutions and their employees who, by participating in the competition, have the chance to obtain co-financing for their research project. The initiative will receive the support of distinguished experts cooperating with key scientific centres in Poland, who, along with the competition Organisers will select the best projects from among the submissions from all over the country. Maciej Wieczorek, CEO of Celon Pharma S.A.: In our everyday work we strongly believe that the combination of passion, knowledge and entrepreneurship can be an effective source of innovation in the pharmaceutical industry. This is our mission which we peruse on a daily basis in the laboratories of Celon Pharma S.A. by conducting research on modern therapies. Together with Polish scientists we intend to broaden the spectrum of our research projects by including aspects related to lung diseases. We believe in the joint success of science and business. Monika Lamparska – Przybysz, Head of the Innovative Medicines Research and Development Department in Celon Pharma S.A.: The competition allows for the participation of all scientists who are conducting research and e.g. have a confirmed research thesis which is associated with the theme of the competition's first edition, i.e. inflammatory processes in lung diseases. We have simplified the formalities necessary to sign up for the competition to a minimum; an Application filled out in accordance with the template presented on our website is sufficient. We focus on effective dialogue with the scientific community in search of interesting projects which we would be able to develop together in our laboratories. The projects will be subject to expert evaluation performed by outstanding professionals whose knowledge and experience will help us select the best submissions.

The theme of the first edition of the competition is: Inflammatory processes in lung diseases, and the following issues will be covered:

  • In vitro and In vivo models to be used in studies on molecular mechanisms of asthma and COPD
  • molecular mechanisms and biomarkers for the development of asthma and COPD
  • new therapeutic objectives with particular focus on treatment of asthma resistant to corticosteroid treatment
  • targeted therapies in asthma and COPD
  • the role of AS/STAT and PI3K pathways in pathogenesis of lung diseases of inflammatory origin

Applications for stage one can be submitted between 15/05/2013 and 10/06/2013. Applications which pass the formal assessment in terms of compliance with the competition rules will be eligible for stage two of the competition, where the entire project will be appraised by the invited experts and the Organiser. The total funding pool in 2013 is PLN 400,000.

More information about the competition procedure and the terms of use can be found at:

Information for the press is provided by:
Celon Pharma S.A. Press Office
Małgorzata Siewierska,
[email protected], 602 301 215


Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. It was founded in 2002 by a man with a vision, passion, interdisciplinary knowledge and experience in this line of business – Maciej Wieczorek. The primary objective of the company is the manufacturing of specialist prescription drugs which improve quality of life of patients and constitute an answer to their unmet clinical needs. Celon Pharma S.A. has two fully equipped laboratories at its disposal, dedicated to research and development (R&D) of medicinal products, both generic and innovative. Two of Celon Pharma S.A's production plants have appropriate GMP (Good Manufacturing Practice) authorisations. The main office and the laboratories are located within 30 km from the centre of Warsaw. The company currently has approx. 200 employees. It employs 40 scientists responsible for research and development, half of whom either have a PhD or are in the process of acquiring their PhD.